Astrazeneca Ab

Other

Astrazenela Ab

Peter Robert Bernstein

Michael Balestra

Keith Russell

Per Jonas Malmborg

Dirk Reinhold Weigelt

Michael Quirk

Gunnar Nordvall

Annika Kers

Cyrus Ohnmacht

Katharina Högdin

Ashokkumar Bhikkappa Shenvi

William Frietze

Glen E Ernst

John McCauley

David Nugiel

Jeffrey Albert

Robert Frank Dedinas

Lihong Shen

Bernard Christophe Barlaam

James B Campbell

Cathy Dantzman

Phil Edwards

James Hulsizer

Dan Widzowski

Simon Nicholas Black

Karen Beth Main

Paul Warwick

Ashokkumar Shenyl

Vivian Y Bi

Greg Christoph

Jean M Surian

Richard J R Creekmore

Daniel Korey

Dan B Brown

Stewart D Jolly

James A Osborn

Alan S Kirschner

Simon D Broady

Scott W Grimm

Dirk Weigelt

Katharina HÖGDIN

Katharina Hogdin

Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.

NMDA antagonist prodrugs

The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.

Ethanamine compounds and methods of using the same

11-piperazin-1-yldibenzo[b,f][1,4]thiazepine, compositions thereof, preparations thereof, formulations thereof, prodrugs thereof and pharmaceutical uses thereof.

Crystalline forms

Ethanamine compounds and methods of using the same 545

The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R, R, R, R, R, R, R, R, R, R, X, X, Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK) receptor. In particular, these compounds are useful in the treatment of diseases in which Substance P is involved such as, for example, major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, chronic obstructive pulmonary disorder (COPD), hypertension, migraine, bladder hypermotility, and urticaria.

Neurokinin antagonists for use as medicaments

Compounds of the formula (I) for use as an estrogen receptor-&#x3b2;-selective ligand are described wherein: X is O or S; and R, RRare as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.

Therapeutic benzoxazole compounds

A compound of the formula:wherein R, R, R, R, R, R, Xand Xare as defined in the specification useful for the treatment of diseases in which action of the neurokinin 1 receptor is implicated, methods of using such compounds and pharmaceutical compositions comprising such compounds.

N-(2-phenyl-3-aminopropyl)naphthamides

Compounds having the general formulawherein R, R, R, X, X, R, R, R, R, R, n, Y and Z are as defined in the specification, methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

Cyclized benzamide neurokinin antagonists for use in therapy

Compounds having the general formulawherein R, R, R, R, R, Xand Xare as defined in the specification, methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

Naphthamide neurokinin antagonists for use as medicaments

Compounds having the general formulawherein R, R, R, R, R, R, R, R, R, R, X, X, Y, Z and n are as defined in the specification, methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

Compounds

Neurokinin-1 receptor antagonists

Growing community of inventors

Rose Valley, PA, United States of America

Peter Robert Bernstein